Anixa Biosciences (ANIX) announced the completion of the final patient visit in its breast cancer vaccine clinical trial. This novel vaccine, invented at Cleveland Clinic, is being developed in partnership with Cleveland Clinic, and the Phase 1 trial is fully funded by a grant from the U.S. Department of Defense. Cleveland Clinic will present full clinical results at the San Antonio Breast Cancer Symposium on December 11, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa announces final results from Phase 1 trial of breast cancer vaccine
- Anixa Biosciences: Promising Clinical Progress and Financial Stability Underpin Buy Rating
- Anixa Biosciences files $200M mixed securities shelf
- Promising Advancements and Strategic Positioning Propel Anixa Biosciences to a Buy Rating
- Anixa completes dosing of fourth cohort in Phase 1 trial of CAR-T/CER-T therapy